This literature review broadly examines disability in Alzheimer's disease (AD). The paper addresses the various types of disability in AD, as well as the presumed causes and the economic and social costs of such disability. The influence of various types of treatment of disability, particularly pharmacological is addressed, as are directions for future research.
Get full access to this article
View all access options for this article.
References
1.
Barberger-GateauP., FabrigouleC., AmievaH., HelmerC., & DartiguesJ.F. (2002). The disablement process: A conceptual framework for dementia-associated disability. Dementia and Geriatric Cognitive Disorders, 13, 60–66.
2.
BaumC., EdwardsD., YonanC., & StorandtM. (1996). The relation of neuropsychological test performance to performance of functional tasks in dementia of the Alzheimer type. Archives of Clinical Neuropsychology, 11, 69–75.
3.
DemersL., OremusM., PerraultA., ChampouxN., & WolfsonC. (2000). Review of outcome measurement instruments in Alzheimer's disease drug trials: Psychometric properties of functional and quality of life scales. Journal of Geriatric Psychiatry and Neurology, 13, 170–180.
4.
DorenlotP., HarounM., BigeV., HenrardJ.C., & AnkriJ. (2005). Major depression as a risk factor for early institutionalization of dementia patients living in the community. International Journal of Geriatric Psychiatry, 20, 471–478.
5.
EspirituD.A., RashidH., MastB., FitzgeraldJ., SteinbergJ., & LichtenbergP. (2001). Depression, cognitive impairment and function in Alzheimer's disease. International Journal of Geriatric Psychiatry, 16, 1098–1103.
6.
FariasS., HarrellE., NeumannC., & HoutzA. (2003). The relationship between neuropsychological performance and daily functioning in individuals with Alzheimer's disease: Ecological validity of neuropsychological tests. Archives of Clinical Neuropsychology, 18, 655–672.
7.
FeldmanH., GauthierS. L., HeckerJ., VellasB., EmirB., MasteyV., SubbiahP. & The Donepezil MSAD Study Investigators Group. (2003). Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect of caregiver burden. Journal of the American Geriatrics Society, 51, 737–744.
8.
GreenR. C., CupplesL. A., BenkeK. S., EdekiT., GriffithP. A., WilliamsM., HippsY., Graff-RadfordN., BachmanD., FarrerL. A., & Mirage Study Group. Risk of dementia among white and African American relatives of patients with Alzheimer disease. Journal of the American Medical Association, 287, 329–336.
9.
HerbertL. E., ScherrP. A., BieniasJ. L., BennettD. A. & EvansD. A. (2003). Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Archives of Neurology, 60, 119–122.
10.
LeungG.M., YeungR.Y.T., ChiI., & ChuL.W. (2003). The economics of Alzheimer disease. Dementia and Geriatric Cognitive Disorders, 15, 34–43.
11.
LoewensteinD.A., RubertM.P., ArguellesT., & DuaraR. (1995). Neuropsychological test performance and prediction of functional capacities among Spanish-speaking and English-speaking patients with dementia. Archives of Clinical Neuropsychology, 10, 75–88.
12.
LomaxC.L., BrownR.G., & HowardR.J. (2004). Measuring disability in patients with neurodegenerative disease using the “Yesterday Interview”. International Journal of Geriatric Psychiatry, 19, 1058–1064.
13.
LyketsosC. G., LopezO., JonesB., FitzpatrickA. L., BreitnerJ., & DeKoskyS. (2002). Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the Cardiovascular Health Study. Journal of the American Medical Association, 288, 1475–1483.
14.
MarshallG.A., FairbanksL.A., TekinS., VintersH.V., & CummingsJ.L. (2006). Neuropathologic correlates of activities of daily living in Alzheimer disease. Alzheimer Disease and Associated Disorders, 20, 56–59.
15.
McDanielK.D., EdlandS.D., HeymanA., & the CERAD Clinical Investigators (1995). Relationship between level of insight and severity of dementia in Alzheimer disease. Alzheimer Disease and Associated Disorders, 9, 101–104.
MohsR.C., DoodyR.S., MorrisJ.C., IeniJ.R., RogersS.L., PerdomoC.A., & PrattR.D. (2001). A 1–year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology, 57, 481–488.
18.
MokW.Y.W., ChuL.W., ChungC.P., ChanN.Y., & HuiS.L. (2004). The relationship between non-cognitive symptoms and functional impairment in Alzheimer's disease. International Journal of Geriatric Psychiatry, 19, 1040–1046.
19.
MuoR., SchindlerA., VerneroI., SchindlerO., FerrarioE., & FrisoniG.B. (2005). Alzheimer's disease-associated disability: An ICF approach. Disability and Rehabilitation, 27, 1405–1413.
20.
NeumannP.J., HermannR.C., KuntzK.M., ArakiS.S., DuffS.B., LeonJ., BerenbaumP.A., GoldmanP.A., WilliamsL.W., & WeinsteinM.C. (1999). Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology, 52, 1138–1145.
21.
RiceD. P., FoxP. J., MaxW., WebberP. A., LindemanD. A., HauckW. W., SeguraE. (1993). The economic burden of Alzheimer's disease care. Health Affairs, 12, 165–176.
22.
RogersS.L., FarlowM.R., DoodyR.S., MohsR., FriedhoffL.T., & The Donepezil Study Group. (1998). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology, 50, 136–145.
23.
ShahA., & JenkinsR. (2003). “Value for money” in treating Alzheimer's disease with the new cholinesterase inhibitors. International Journal of Psychiatry in Clinical Practice, 7, 45–47.
24.
SinkK.M., HoldenK.F., & YaffeK. (2005). Pharmacological treatment of neuropsychiatric symptoms of dementia. Journal of the American Medical Association293, 596–608.
25.
SouetreE.J., QingW., VigoureuxI., DartiguesJ., LozetH., LacomblezL., & DerouesneC. (1995). Economic analysis of Alzheimer's disease in outpatients: Impact of symptom severity. International Psychogeriatrics, 7, 115–122.
26.
StarnsM. K., KarnerT. X., & MontgomeryR. J. V. (2002). Exemplars of successful Alzheimer's demonstration project. Home Health Care Services Quarterly, 21, 141–175.
27.
SuhG.H., JuY.S., YeonB.K., & ShahA. (2004). A longitudinal study of Alzheimer's disease: Rates of cognitive and functional decline. International Journal of Geriatric Psychiatry, 19, 817–824.
28.
TownsendD. & KosloskiK. (2002). Factors related to client satisfaction with community-based respite services. Home Health Care Services Quarterly, 21, 89–106.
29.
WardA., CaroJ.J., GetsiosD., IshakK., O'BrienJ., & BullockR. (2003). Assessment of health economics in Alzheimer's disease (AHEAD): Treatment with galantamine in the UK. International Journal of Geriatric Psychiatry, 18, 740–747.
30.
YaffeK., FoxP., NewcomerR., SandsL., LindquistK., DaneK., & CovinskyK.E. (2002). Patient and caregiver characteristics and nursing home placement in patients with dementia. Journal of the American Medical Association287, 2090–2097.
